Key Advances in Hormone Receptor—Positive Breast Cancer - prIME Oncology
Clinical Spotlight
Clinical Spotlight

Key Advances in Hormone Receptor—Positive Breast Cancer

Updates From the 2018 Oncology Annual Meeting in Chicago

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

This breast cancer thought-leader discussion, with associated slide deck and eNewsflash, provides participants with valuable updates and expert perspectives on exciting new data in hormone receptor (HR)-positive breast cancer released at the 2018 Oncology Annual Meeting in Chicago.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Newsflash

Newsflash

Release Date

Release Date

Jun 7, 2018

Expiration Date

Jun 7, 2019

Featured Experts

  • Robert Coleman, MD, FRCP, FRCPE, Medical Director, prIME Oncology, University of Sheffield
    Weston Park Hospital, Sheffield, United Kingdom
  • Hikmat Abdel-Razeq, MD, King Hussein Cancer Center, Amman, Jordan
  • Guy Jerusalem, MD, PhD, Centre Hospitalier Universitaire de Liège, Liège, Belgium

Featured Abstracts

Abstract #1000 Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3

Abstract #1001 Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant

Abstract #1002 Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer

Abstract #1005 Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

Abstract #LBA1006 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Featured Experts

  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Hikmat Abdel-Razeq, MDKing Hussein Cancer Center
    Amman, Jordan
  • Guy Jerusalem, MD, PhDCentre Hospitalier Universitaire de Liège
    Liège, Belgium

This educational activity is specifically designed for oncologists and other healthcare professionals involved in the management of patients with HR-positive breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate emerging clinical trial data investigating the safety and efficacy of combination approaches for HR-positive, HER2-negative breast cancer
  • Select appropriate treatment approaches for HR-positive, HER2-negative breast cancer and identify the optimal sequence of treatment options

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abdel-Razeq has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jerusalem has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, Novartis Oncology, and Pfizer. He also disclosed performing contracted research for Novartis Oncology and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research for or research support from Amgen and Bayer
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.